Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 115 of 6351
-
New immunotherapy targets tough pancreatic cancers in early trial
Disease control OngoingThis is a Phase 1/2 study to assess the safety and efficacy of ELI-002 7P immunotherapy (a lipid-conjugated immune-stimulatory oligonucleotide \[Amph-CpG-7909\] plus a mixture of lipid-conjugated peptide-based antigens \[Amph-Peptides 7P\]) as adjuvant treatment in subjects with …
Phase 1/2 • Sponsor: Elicio Therapeutics • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Can a new drug tame severe childhood epilepsy?
Disease control OngoingThe goal of this trial is to learn about the effect of PRAX-222 in pediatric participants with early onset SCN2A developmental and epileptic encephalopathy (DEE), aged 2 to 18 years.
Phase 1/2 • Sponsor: Praxis Precision Medicines • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Could a simple nutrient shield babies from Alcohol's harm in the womb?
Disease control Recruiting nowAlthough the adverse effects associated with prenatal alcohol exposure (PAE) are well known, many women continue to drink heavily during pregnancy, putting their infants at risk for fetal alcohol spectrum disorders. Animal studies have shown that choline supplementation can mitig…
Phase 2 • Sponsor: Wayne State University • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Can a new drug combo outsmart Triple-Negative breast cancer?
Disease control CompletedThis is a multicenter, open-label, two-stage Phase II clinical study to evaluate the safety and efficacy of BEBT-209 capsule in combination with carboplatin and gemcitabine for the treatment of advanced triple-negative breast cancer (TNBC).
Phase 2 • Sponsor: BeBetter Med Inc • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New program aims to save LGBTQ+ youth from suicide
Symptom relief OngoingThe overarching goal of this study is to evaluate a newly-developed suicide prevention program for sexual and gender minority youth and emerging adults. After development of the intervention program, a randomized controlled trial will be conducted to test its preliminary efficacy…
Sponsor: San Diego State University • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
Triple threat: new vaccine aims to tackle three salmonella strains at once
Vaccine OngoingThis is an age-descending, randomized, placebo-controlled trial that will evaluate the safety and immunogenicity of a Trivalent Salmonella conjugate vaccine (TSCV). The trial will proceed from adults, to children, to toddlers, and then to infants.
Phase 2 • Sponsor: University of Maryland, Baltimore • Aim: Vaccine
Last updated Jul 01, 2026 00:00 UTC
-
Can a new targeted drug outperform standard therapy for advanced head and neck cancer?
Disease control Recruiting nowThe objective of this study is to compare the efficacy and safety of MRG003 versus cetuximab/methotrexate as second/third line of therapy in patients with RM-SCCHN who have previously failed PD-1 (L1) inhibitors and platinum-based therapy.
Phase 3 • Sponsor: Lepu Biopharma Co., Ltd. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New drug combo aims to stop prostate Cancer's return in High-Risk men
Disease control OngoingResearchers are looking for a better way to treat men at high-risk of biochemical recurrence (BCR) of prostate cancer. BCR means that in men who had prostate cancer and were treated by either surgery and/ or radiation therapy, the blood level of a specific protein called PSA ris…
Phase 3 • Sponsor: Bayer • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Oxygen therapy shows promise in brain cancer fight
Disease control OngoingThis clinical trial is testing the safety and efficacy of NanO2TM administered via intravenous infusion in combination with standard radiation and chemotherapy. NanO2TM is being developed to increase the amount of oxygen delivered to tumors which is hoped to increase the effecti…
Phase 2 • Sponsor: NuvOx LLC • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New daily pill could keep breast cancer from coming back
Disease control Recruiting nowThis is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed definitive locoregional therapy (with or wit…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New pill combo aims to keep breast cancer from returning
Disease control OngoingThis is a Phase III, randomized, double-blind, parallel, multi-center trail to evaluate the efficacy and safety of TQB3616 capsule combined with endocrine compared to placebo compared with endocrine in HR-positive and HER2-negative breast cancer adjuvant therapy. Approximately 19…
Phase 3 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Could a Two-Drug combo stop repeat heart attacks?
Disease control OngoingThe primary objective was to evaluate the effect of PCSK 9 Inhibitor (initiated within 4 h from PCI for the culprit lesion) with high-intensity statin treatment, compared to placebo with high-intensity statin treatment, on cardiovascular events (including cardiovascular death, my…
Sponsor: Nanjing First Hospital, Nanjing Medical University • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New hope for hard-to-treat myeloma: teclistamab takes on standard combos
Disease control OngoingThe purpose of this study is to compare the efficacy of teclistamab with PVd/Kd in Part 1 and to further characterize safety and efficacy of an alternative dosing for teclistamab in Part 2 in participants with relapsed or refractory multiple myeloma.
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Nasal spray vaccine aims to shield children from RSV
Vaccine Stopped earlyThis study is a Phase 1, randomized, double-blind, placebo-controlled, dose-escalation clinical trial to evaluate the safety of and immune response to CodaVax-RSV in healthy children. They will be vaccinated in spring to early autumn 2023 and followed through the 2023-24 RSV seas…
Phase 1 • Sponsor: Codagenix, Inc • Aim: Vaccine
Last updated Jul 17, 2026 00:00 UTC
-
Moderna's Next-Gen COVID shot put to the test in 13,000+ people
Prevention CompletedThe purpose of this study (Part 1 and Part 2) is to evaluate the relative vaccine efficacy (rVE), safety, reactogenicity, and immunogenicity of mRNA-1283.222 versus mRNA-1273.222 (Part 1) and mRNA-1283.815 versus mRNA-1273.815 (Part 2).
Phase 3 • Sponsor: ModernaTX, Inc. • Aim: Prevention
Last updated Jun 27, 2026 12:28 UTC
-
New polio vaccine trial aims to boost eradication efforts
Vaccine Recruiting nowThe purpose of this clinical trial is to assess the safety and tolerability (primary objective), immunogenicity (primary and secondary objectives), fecal shedding of vaccine viruses (secondary objective) and the potential for neurovirulence of shed virus (secondary objective) of …
Phase 2 • Sponsor: PATH • Aim: Vaccine
Last updated Jun 27, 2026 08:09 UTC
-
Could a cancer drug spare some patients from colon surgery?
Disease control Recruiting nowThis is a Phase II, single arm study looking at the rate of major clinical response and non-operative management in Stage II and III colon cancer after 18 weeks (up to 6 cycles) of neoadjuvant dostarlimab.
Phase 2 • Sponsor: University of Iowa • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New bladder cancer combo aims to beat standard treatment
Disease control OngoingThe purpose of this study is to compare event-free survival (EFS) in participants with Bacillus Calmette-Guerin (BCG)-naive high-risk non-muscle invasive bladder cancer (HR-NMIBC), including high-grade papillary Ta, any T1, or carcinoma in situ (CIS), between TAR-200 plus cetreli…
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New Two-Drug combo aims to stop leprosy spread in its tracks
Prevention Recruiting nowThere will be two study arms. Arm 1 will be the intervention arm in which there will be provided BE-PEP to all persons residing within 100 meters of an index case, to be repeated after four weeks for household contacts. Arm 2 will be the comparator arm in which the WHO recommende…
Phase 3 • Sponsor: Institute of Tropical Medicine, Belgium • Aim: Prevention
Last updated Jun 27, 2026 12:36 UTC
-
New combo treatment could improve outcomes in major stroke
Disease control CompletedTo assess the effect of intravenous tenecteplase plus endovascular thrombectomy (EVT) compared to EVT alone on 4.5 to 24 hours after stroke due to basilar artery occlusion.
Phase 3 • Sponsor: The First Affiliated Hospital of University of Science and Technology of China • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC